With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.
Opko Health (OPK) posted earnings and revenue that topped analysts' estimates for the 2016 second quarter following Monday's market close.
Cramer wants you to stick with Abbvie and says Cepheid is working.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.